Anastasiya G. Samoylova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anastasiya G. Samoylova has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Irina A. Vasilyeva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
17 shared publications - O. V. Lovacheva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation
12 shared publications - Galina Mozhokina
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation
11 shared publications - A. I. Gayda
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
10 shared publications - Marija I. Romanova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
10 shared publications - Anna V. Abramchenko
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; Pirogov Russian National Research Medical University, Russian Ministry of Health
9 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8273
Frequency of Post-Treatment Recurrence After Short-Course Regimens for Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis
Background/Objectives: Short-course regimens (SCRs) are increasingly used to treat drug-resistant tuberculosis (DR-TB), but data on post-treatment recurrence remain limited. We aimed to estimate the frequency of post-treatment recurrence after SCRs and compare recurrence between SCRs and comparator regimens. Methods: We conducted a systematic review and meta-analysis of clinical studies reporting treatment duration, post-treatment follow-up, and recurrent tuberculosis episodes after SCRs for DR-TB. The primary single-arm analysis used a binomial-normal random-effects generalized linear mixed model (GLMM) based on r/A, retaining zero-event cohorts without a continuity correction. Comparative analyses used pooled risk ratios (RRs) and person-time-adjusted incidence rate ratios (IRRs). Results: Twenty-five studies contributed 26 SCR cohorts. In the primary analysis, 98 recurrent tuberculosis episodes occurred among 6954 patients; the pooled proportion was 1.24% (95% confidence interval [CI], 0.79–1.93%; 95% prediction interval, 0.24–6.21%). The pooled proportion was 1.20% (95% CI, 0.70–2.03%) for fully oral SCRs, 1.57% (0.85–2.85%) for pretomanid-containing SCRs, 1.55% (0.93–2.56%) for SCRs lasting ≤ 39 weeks, and 1.95% (1.20–3.15%) for SCRs lasting ≤ 36 weeks. In the overall comparative analysis, no statistically significant difference in post-treatment recurrence was observed between SCRs and comparator regimens: the pooled RR was 1.35 (95% CI, 0.34–5.40), and the person-time-adjusted IRR was 1.25 (95% CI, 0.50–3.15). In the randomized controlled trial (RCT) subset, the pooled RR indicated a higher recurrence risk with SCRs (RR, 2.72; 95% CI, 1.25–5.89), whereas the corresponding person-time-adjusted estimate did not show a statistically significant difference (IRR, 1.66; 95% CI, 0.81–3.43). This divergence indicates that comparative estimates are sensitive to how post-treatment follow-up duration is accounted for. Meta-regression identified no statistically significant associations between recurrence frequency and the examined cohort-level clinical characteristics. The certainty of evidence, assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework, was low for the estimated recurrence frequency after fully oral SCRs, very low for the subgroup estimates, and low for the comparative estimates. Conclusions: These findings indicate a low frequency of post-treatment tuberculosis recurrence after SCRs and support the durability of treatment outcomes achieved with these regimens. However, substantial between-study heterogeneity and differences in post-treatment follow-up limit the interpretation of the pooled estimate as a uniform long-term recurrence risk. Further studies with standardized follow-up beginning at treatment completion are needed to provide more precise estimates of long-term outcomes after SCRs.
- 23 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8273
Open AccessFrequency of Post-Treatment Recurrence After Short-Course Regimens for Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis
Background/Objectives: Short-course regimens (SCRs) are increasingly used to treat drug-resistant tuberculosis (DR-TB), but data on post-treatment recurrence remain limited. We aimed to estimate the frequency of post-treatment recurrence after SCRs and compare recurrence between SCRs and comparator regimens. Methods: We conducted a systematic review and meta-analysis of clinical studies reporting treatment duration, post-treatment follow-up, and recurrent tuberculosis episodes after SCRs for DR-TB. The primary single-arm analysis used a binomial-normal random-effects generalized linear mixed model (GLMM) based on r/A, retaining zero-event cohorts without a continuity correction. Comparative analyses used pooled risk ratios (RRs) and person-time-adjusted incidence rate ratios (IRRs). Results: Twenty-five studies contributed 26 SCR cohorts. In the primary analysis, 98 recurrent tuberculosis episodes occurred among 6954 patients; the pooled proportion was 1.24% (95% confidence interval [CI], 0.79–1.93%; 95% prediction interval, 0.24–6.21%). The pooled proportion was 1.20% (95% CI, 0.70–2.03%) for fully oral SCRs, 1.57% (0.85–2.85%) for pretomanid-containing SCRs, 1.55% (0.93–2.56%) for SCRs lasting ≤ 39 weeks, and 1.95% (1.20–3.15%) for SCRs lasting ≤ 36 weeks. In the overall comparative analysis, no statistically significant difference in post-treatment recurrence was observed between SCRs and comparator regimens: the pooled RR was 1.35 (95% CI, 0.34–5.40), and the person-time-adjusted IRR was 1.25 (95% CI, 0.50–3.15). In the randomized controlled trial (RCT) subset, the pooled RR indicated a higher recurrence risk with SCRs (RR, 2.72; 95% CI, 1.25–5.89), whereas the corresponding person-time-adjusted estimate did not show a statistically significant difference (IRR, 1.66; 95% CI, 0.81–3.43). This divergence indicates that comparative estimates are sensitive to how post-treatment follow-up duration is accounted for. Meta-regression identified no statistically significant associations between recurrence frequency and the examined cohort-level clinical characteristics. The certainty of evidence, assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework, was low for the estimated recurrence frequency after fully oral SCRs, very low for the subgroup estimates, and low for the comparative estimates. Conclusions: These findings indicate a low frequency of post-treatment tuberculosis recurrence after SCRs and support the durability of treatment outcomes achieved with these regimens. However, substantial between-study heterogeneity and differences in post-treatment follow-up limit the interpretation of the pooled estimate as a uniform long-term recurrence risk. Further studies with standardized follow-up beginning at treatment completion are needed to provide more precise estimates of long-term outcomes after SCRs.
- Open Access
- 24 September 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2154
Mycobacteriophages: An Integrated Platform for Rapid Diagnosis and Targeted Therapy of Tuberculosis Infection
The global spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) demands fundamentally new approaches combining diagnostic speed and therapeutic efficacy. Within the strategy of personalised medicine, the lytic mycobacteriophage D29 represents a promising tool for both phenotypic drug susceptibility testing and the targeted delivery of therapeutic agents to the infection site. We developed a two-component platform based on D29: (1) a diagnostic test system combining a rapid anti-mycobacterial susceptibility testing (AMST) module, which detects phage D29 replication in drug-resistant isolates via multiplex real-time PCR; and (2) a liposomal therapeutic formulation. Therapeutic efficacy was evaluated in C57BL/6 mice (n = 55) with experimental pulmonary tuberculosis receiving liposomal D29 either aerosolised (inhalation chamber) or intranasally. Bacterial burden (CFU/lung) was assessed at days 3 and 14 post-therapy. Pharmacokinetics were studied in 90 mice using the double-layer agar method. The diagnostic test showed an average sensitivity and specificity of 90.0% and 96.3% across nine drugs, with results available within five days. The lyophilised components and phage remained stable for 12 months. Aerosol therapy demonstrated a trend towards a higher efficacy compared to intranasal administration: the median CFU/lung at day 3 was 107 (i.e., one hundred and seven) vs. 23,500 (control 65,000); 60% of aerosol-treated animals achieved ≤200 CFU/lung (not statistically significant, p = 0.089). Both routes significantly outperformed controls (p < 0.01 and p < 0.05). Pharmacokinetics revealed exclusive lung tropism with peak concentrations at 5 min (1.9 × 103–5.1 × 104 PFU/organ) and phage levels falling below the limit of detection (3 PFU/organ) within 24 h. Infected lungs showed significantly higher phage titres than uninfected ones, indicating in vivo replication. Safety studies showed no significant toxicity, immunogenicity, or local irritation. The integrated D29-based platform represents a comprehensive, integrated diagnostic–therapeutic solution covering the full “diagnosis–therapy” cycle. The test system provides rapid phenotypic drug susceptibility profiling, while the liposomal phage demonstrates potent therapeutic activity and favourable pharmacokinetics, supporting its clinical translation.
- 24 September 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2154
Open AccessMycobacteriophages: An Integrated Platform for Rapid Diagnosis and Targeted Therapy of Tuberculosis Infection
The global spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) demands fundamentally new approaches combining diagnostic speed and therapeutic efficacy. Within the strategy of personalised medicine, the lytic mycobacteriophage D29 represents a promising tool for both phenotypic drug susceptibility testing and the targeted delivery of therapeutic agents to the infection site. We developed a two-component platform based on D29: (1) a diagnostic test system combining a rapid anti-mycobacterial susceptibility testing (AMST) module, which detects phage D29 replication in drug-resistant isolates via multiplex real-time PCR; and (2) a liposomal therapeutic formulation. Therapeutic efficacy was evaluated in C57BL/6 mice (n = 55) with experimental pulmonary tuberculosis receiving liposomal D29 either aerosolised (inhalation chamber) or intranasally. Bacterial burden (CFU/lung) was assessed at days 3 and 14 post-therapy. Pharmacokinetics were studied in 90 mice using the double-layer agar method. The diagnostic test showed an average sensitivity and specificity of 90.0% and 96.3% across nine drugs, with results available within five days. The lyophilised components and phage remained stable for 12 months. Aerosol therapy demonstrated a trend towards a higher efficacy compared to intranasal administration: the median CFU/lung at day 3 was 107 (i.e., one hundred and seven) vs. 23,500 (control 65,000); 60% of aerosol-treated animals achieved ≤200 CFU/lung (not statistically significant, p = 0.089). Both routes significantly outperformed controls (p < 0.01 and p < 0.05). Pharmacokinetics revealed exclusive lung tropism with peak concentrations at 5 min (1.9 × 103–5.1 × 104 PFU/organ) and phage levels falling below the limit of detection (3 PFU/organ) within 24 h. Infected lungs showed significantly higher phage titres than uninfected ones, indicating in vivo replication. Safety studies showed no significant toxicity, immunogenicity, or local irritation. The integrated D29-based platform represents a comprehensive, integrated diagnostic–therapeutic solution covering the full “diagnosis–therapy” cycle. The test system provides rapid phenotypic drug susceptibility profiling, while the liposomal phage demonstrates potent therapeutic activity and favourable pharmacokinetics, supporting its clinical translation.
- Open Access
- 15 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8227
Use of Porphyrin Precursors as a Novel Approach for Detection of Mycobacterium tuberculosis
Tuberculosis remains one of the leading infectious diseases worldwide, which is why new approaches are being developed as a foundation for future diagnostic methods. One promising strategy relies on porphyrins as biomarkers for the detection of Mycobacterium tuberculosis using fluorescence spectroscopy. Previous attempts have been made to detect microorganisms based on their porphyrin production. However, insufficient endogenous porphyrin production limits the applicability of this approach for mycobacterial detection. As a proof-of-principle study, we investigated the feasibility of using exogenous precursors to enhance porphyrin accumulation with the aim of detecting mycobacterial growth by means of fluorescence spectroscopy. The introduction of these precursors resulted in a significantly higher fluorescence signal intensity, making it possible to detect Mycobacterium tuberculosis and identify potential contamination.
- 15 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8227
Open AccessUse of Porphyrin Precursors as a Novel Approach for Detection of Mycobacterium tuberculosis
Tuberculosis remains one of the leading infectious diseases worldwide, which is why new approaches are being developed as a foundation for future diagnostic methods. One promising strategy relies on porphyrins as biomarkers for the detection of Mycobacterium tuberculosis using fluorescence spectroscopy. Previous attempts have been made to detect microorganisms based on their porphyrin production. However, insufficient endogenous porphyrin production limits the applicability of this approach for mycobacterial detection. As a proof-of-principle study, we investigated the feasibility of using exogenous precursors to enhance porphyrin accumulation with the aim of detecting mycobacterial growth by means of fluorescence spectroscopy. The introduction of these precursors resulted in a significantly higher fluorescence signal intensity, making it possible to detect Mycobacterium tuberculosis and identify potential contamination.
- Open Access
- 16 July 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (3) , 107-117
Phenotypic and Molecular Genetic Resistance of Mycobacterium tuberculosis to Fluoroquinolones: A Literature Review
Fluoroquinolones are essential drugs for the treatment of drug-resistant tuberculosis; however, the rise in resistance to these agents significantly reduces treatment efficacy. This review summarizes current data on the molecular genetic and phenotypic mechanisms of Mycobacterium tuberculosis resistance to fluoroquinolones. Particular attention is focused on mutations in the gyrA and gyrB genes encoding DNA gyrase, the primary target of fluoroquinolones. Mutations within the QRDR of gyrA are the major determinants of resistance and are associated with an increase in the minimum inhibitory concentrations of fluoroquinolones. This review examines the role of alternative resistance mechanisms, including efflux pump systems and glpK -associated adaptations, as well as the importance of the WHO Catalogue of Mutations for variant interpretation. The integration of phenotypic and molecular diagnostic approaches is essential for the effective detection and control of drug-resistant tuberculosis.
- 16 July 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (3) , 107-117
Open AccessPhenotypic and Molecular Genetic Resistance of Mycobacterium tuberculosis to Fluoroquinolones: A Literature Review
Fluoroquinolones are essential drugs for the treatment of drug-resistant tuberculosis; however, the rise in resistance to these agents significantly reduces treatment efficacy. This review summarizes current data on the molecular genetic and phenotypic mechanisms of Mycobacterium tuberculosis resistance to fluoroquinolones. Particular attention is focused on mutations in the gyrA and gyrB genes encoding DNA gyrase, the primary target of fluoroquinolones. Mutations within the QRDR of gyrA are the major determinants of resistance and are associated with an increase in the minimum inhibitory concentrations of fluoroquinolones. This review examines the role of alternative resistance mechanisms, including efflux pump systems and glpK -associated adaptations, as well as the importance of the WHO Catalogue of Mutations for variant interpretation. The integration of phenotypic and molecular diagnostic approaches is essential for the effective detection and control of drug-resistant tuberculosis.
- Open Access
- 16 July 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (3) , 88-97
Pretomanid: From Development to the Implementation of Short-Term Tuberculosis Chemotherapy Regimens: A Literature Review
The objective: to analyze preclinical and clinical studies on the mechanisms of action, efficacy and safety of the antituberculosis drug pretomanid (PA-824/ F₄₂₀- Pa). Materials and methods: This review presents the results of 48 publications, including clinical trials evaluating the activity and efficacy of pretomanid (PA-824/ F₄₂₀- Pa) – a member of the nitroimidazopyran class developed for treatment of tuberculosis (TB). This drug is effective against both replicating and persistent Mycobacterium tuberculosis (Mtb), particularly under hypoxic conditions. Preclinical studies demonstrated high activity of Pa against both drug-susceptible and drug-resistant M. tuberculosis. Pa became a key component of the short-term, all-oral regimens, such as BPaL (bedaquiline, pretomanid, and linezolid), for treatment of multidrug-resistant and pre-extensively drug-resistant TB Phase III clinical trials (Nix-TB, ZeNix-TB, and TB-PRACTECAL) confirmed that these regimens achieve cure in just 6 months with a favorable safety profile. Consequently, the duration of effective treatment for drug-resistant TB becomes comparable to that for drug-susceptible TB.
- 16 July 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (3) , 88-97
Open AccessPretomanid: From Development to the Implementation of Short-Term Tuberculosis Chemotherapy Regimens: A Literature Review
The objective: to analyze preclinical and clinical studies on the mechanisms of action, efficacy and safety of the antituberculosis drug pretomanid (PA-824/ F₄₂₀- Pa). Materials and methods: This review presents the results of 48 publications, including clinical trials evaluating the activity and efficacy of pretomanid (PA-824/ F₄₂₀- Pa) – a member of the nitroimidazopyran class developed for treatment of tuberculosis (TB). This drug is effective against both replicating and persistent Mycobacterium tuberculosis (Mtb), particularly under hypoxic conditions. Preclinical studies demonstrated high activity of Pa against both drug-susceptible and drug-resistant M. tuberculosis. Pa became a key component of the short-term, all-oral regimens, such as BPaL (bedaquiline, pretomanid, and linezolid), for treatment of multidrug-resistant and pre-extensively drug-resistant TB Phase III clinical trials (Nix-TB, ZeNix-TB, and TB-PRACTECAL) confirmed that these regimens achieve cure in just 6 months with a favorable safety profile. Consequently, the duration of effective treatment for drug-resistant TB becomes comparable to that for drug-susceptible TB.
- Open Access
- 16 July 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (3) , 16-25
Safety Profile of a Modified All-Oral Short-Term Regimen for Drug-Resistant Tuberculosis: an Experimental Assessment
The objective: to evaluate the toxicity of bedaquiline and delamanid combined with linezolid or sutezolid (Szd) in a rat model. Materials and methods: Rats in the experimental groups (EG) were orally administered Bdq+Dlm+Lzd (EG1) or Bdq+Dlm+Szd (EG2). Rats in the control group (CG) orally received 1% starch gel. For all groups, the administration period lasted 14 days. Subsequently, functional, hematological, biochemical, and pathomorphological tests were conducted, with results compared between the experimental groups and the control group. Results: Prolongation of QT and RR intervals on ECG and similar signs of toxic cardiomyopathy development were observed in rats of both experimental groups, driven by the effects of delamanid and bedaquiline on the cardiac conduction system. Based on functional and morphological criteria, the hepatotoxic properties of the combination containing sutezolid were less pronounced. Evidence of tubulointerstitial nephritis was detected exclusively in EG1 rats. Hematological changes were similar in both experimental groups and transient in nature; however, granulocytopenia, lymphocytopenia, and thrombocytopenia occurred at earlier stages when linezolid was used.
- 16 July 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (3) , 16-25
Open AccessSafety Profile of a Modified All-Oral Short-Term Regimen for Drug-Resistant Tuberculosis: an Experimental Assessment
The objective: to evaluate the toxicity of bedaquiline and delamanid combined with linezolid or sutezolid (Szd) in a rat model. Materials and methods: Rats in the experimental groups (EG) were orally administered Bdq+Dlm+Lzd (EG1) or Bdq+Dlm+Szd (EG2). Rats in the control group (CG) orally received 1% starch gel. For all groups, the administration period lasted 14 days. Subsequently, functional, hematological, biochemical, and pathomorphological tests were conducted, with results compared between the experimental groups and the control group. Results: Prolongation of QT and RR intervals on ECG and similar signs of toxic cardiomyopathy development were observed in rats of both experimental groups, driven by the effects of delamanid and bedaquiline on the cardiac conduction system. Based on functional and morphological criteria, the hepatotoxic properties of the combination containing sutezolid were less pronounced. Evidence of tubulointerstitial nephritis was detected exclusively in EG1 rats. Hematological changes were similar in both experimental groups and transient in nature; however, granulocytopenia, lymphocytopenia, and thrombocytopenia occurred at earlier stages when linezolid was used.
- Open Access
- 30 June 2026
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 103 (3) , 332-340
DNA operon structure optimization for the expression of fluorescent proteins in mycobacteria
Introduction. The use of bacteriophage derivatives, whose growth indicator is a fluorescent signal (fluorophages), seems to be very promising in microbiological analyses. The first mandatory stage of their design (in particular, of fluoromycobacteriophages) is the optimization of the structure of the fluorescent protein operon (FPO) with control of its ability to provide fluorescence of mycobacteria The aim of the study is to construct different variants of FPO in plasmids and compare their expression in mycobacteria by the magnitude of the fluorescent signal. Materials and methods. As part of the pMind plasmid, which is capable of replicating in both Escherichia coli and mycobacteria, FPOs of different structures with the hsp60 promoter producing the TurboGFP protein have been constructed using conventional genetic engineering methods. Plasmids with FPOs were introduced into Mycobacterium smegmatis cells by elecroporanion. Results. The greatest fluorescent signal was provided by FPO, in which the hsp60 ribosome binding site in the 5’-untranslated mRNA region was replaced by that for the gp9 gene of the TM4 phage. The necessity of the presence of a transcription terminator in FPO is shown, as well as the importance of preserving the mRNA structure before the point of translation initiation. Conclusion. The optimal structure of FPO has been selected for its subsequent incorporation into the phage genome. Elements of the operon structure important for the expression of a foreign protein in mycobacteria have been identified.
- 30 June 2026
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 103 (3) , 332-340
Open AccessDNA operon structure optimization for the expression of fluorescent proteins in mycobacteria
Introduction. The use of bacteriophage derivatives, whose growth indicator is a fluorescent signal (fluorophages), seems to be very promising in microbiological analyses. The first mandatory stage of their design (in particular, of fluoromycobacteriophages) is the optimization of the structure of the fluorescent protein operon (FPO) with control of its ability to provide fluorescence of mycobacteria The aim of the study is to construct different variants of FPO in plasmids and compare their expression in mycobacteria by the magnitude of the fluorescent signal. Materials and methods. As part of the pMind plasmid, which is capable of replicating in both Escherichia coli and mycobacteria, FPOs of different structures with the hsp60 promoter producing the TurboGFP protein have been constructed using conventional genetic engineering methods. Plasmids with FPOs were introduced into Mycobacterium smegmatis cells by elecroporanion. Results. The greatest fluorescent signal was provided by FPO, in which the hsp60 ribosome binding site in the 5’-untranslated mRNA region was replaced by that for the gp9 gene of the TM4 phage. The necessity of the presence of a transcription terminator in FPO is shown, as well as the importance of preserving the mRNA structure before the point of translation initiation. Conclusion. The optimal structure of FPO has been selected for its subsequent incorporation into the phage genome. Elements of the operon structure important for the expression of a foreign protein in mycobacteria have been identified.
- 14 May 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (2)
Linezolid Delivery Methods to the Site of Tuberculosis Inflammation: a Systematic Review
50 scientific publications between 2018 and 2025 were analyzed, focusing on drug delivery systems and benefits of linezolid-loaded nanoparticles. Orally administered anti-tuberculosis drugs do not always achieve sufficient bactericidal concentrations at the site of infection, regardless of their serum levels. Consequently, even with treatment adherence, approximately 1% of patients may develop multidrug-resistant tuberculosis (MDR-TB) due to pharmacokinetic variability. This highlights the need for advanced delivery systems that ensure targeted drug release directly into the affected lung tissue. Nanoformulations of linezolid (e.g., dry powders, aerosols) have been developed. These formulations remain stable for up to 6 months and increase bioavailability to 55.2%, enabling dose reduction. This opens up real prospects for lowering the therapeutic dose of the drug.
- 14 May 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (2)
Linezolid Delivery Methods to the Site of Tuberculosis Inflammation: a Systematic Review
50 scientific publications between 2018 and 2025 were analyzed, focusing on drug delivery systems and benefits of linezolid-loaded nanoparticles. Orally administered anti-tuberculosis drugs do not always achieve sufficient bactericidal concentrations at the site of infection, regardless of their serum levels. Consequently, even with treatment adherence, approximately 1% of patients may develop multidrug-resistant tuberculosis (MDR-TB) due to pharmacokinetic variability. This highlights the need for advanced delivery systems that ensure targeted drug release directly into the affected lung tissue. Nanoformulations of linezolid (e.g., dry powders, aerosols) have been developed. These formulations remain stable for up to 6 months and increase bioavailability to 55.2%, enabling dose reduction. This opens up real prospects for lowering the therapeutic dose of the drug.
- 7 May 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 1 (19) , 24-33
Gamma interferon in patients with drug-resistant pulmonary tuberculosis: clinical and cost-effectiveness aspects
Objective : To evaluate the efficacy of gamma interferon (IFN-γ) injections for patients with multidrug-resistant tuberculosis (MDR-TB) undergoing antituberculosis chemotherapy according to current clinical guidelines through a clinical and economic analysis. Material and methods . A clinical-economic model of the two strategies for managing MDR-TB patients was developed. The costeffectiveness of these strategies was determined taking into account only the direct costs of inpatient care. Time-based costs for patient management were calculated, focusing on the period from the start of therapy to the end of the study drug administration (3 months). This included: Period 0 – the start of therapy, days 1–14 plus 3 days for testing to confirm the absence of bacterial excretion; Period 1 – days 18–30 + 3 days for testing; Period 2 – days 34–60 + 3 days for testing; Period 3 – days 64–90 + 3 days for testing. For budget impact analysis we used the difference in costs between the two treatment strategies: antituberculosis chemotherapy with IFN-γ injections (the main group) and antituberculosis chemotherapy without IFN-γ (the control group). Efficiency parameters included sputum conversion rates based on microscopy and the median time to clinical response. Cost-effectiveness ratios were calculated using the clinical efficiency of the compared therapies, taking into account sputum smear conversion rates based on microscopy. The results were verified using a one-factor sensitivity analysis based on the cost-effectiveness ratio within a range of ±30%. Results . Pharmacotherapy costs during the first 14 days of hospitalization were higher in the group treated with IFN-γ (12,347,287.00 rubles) compared with the control group (10,723,532.00 rubles). Due to the clinical response achieved, a significantly larger number of patients in the main group are transferred to outpatient care, and costs in Period 1 for this group tend to decrease (1,394,517.12 rubles), while in the control group they are three times higher (4,138,021.76 rubles). Costs in the control group were 3.8 times higher than in the main group in Period 2, and 3.3 times higher in Period 3. Total costs for inpatient care over the 3-month treatment period with the study drug (the main group) were 1.5 times lower than those in the control group. Furthermore, the results were supported by calculations using the time to clinical response, as determined by microscopic examination. These calculations showed that the treatment in the main group was 25.64% more cost-effective than in the control group. The lower cost-effectiveness ratio in the main group compared to the control group (1,401.51 and 1,802.27, respectively) and the higher clinical efficacy in terms of the main criterion indicate that including IFN-γ in the treatment of MDR-TB patients is more cost-effective and preferable. A one-factor sensitivity analysis based on the cost-effectiveness metric confirmed the robustness of the findings to uncertainties and variations in the input data. Conclusion . The results obtained indicate the economic feasibility of adding IFN-γ as a pathogenetic therapy for MDR-TB in combination with antituberculosis chemotherapy.
- 7 May 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 1 (19) , 24-33
Gamma interferon in patients with drug-resistant pulmonary tuberculosis: clinical and cost-effectiveness aspects
Objective : To evaluate the efficacy of gamma interferon (IFN-γ) injections for patients with multidrug-resistant tuberculosis (MDR-TB) undergoing antituberculosis chemotherapy according to current clinical guidelines through a clinical and economic analysis. Material and methods . A clinical-economic model of the two strategies for managing MDR-TB patients was developed. The costeffectiveness of these strategies was determined taking into account only the direct costs of inpatient care. Time-based costs for patient management were calculated, focusing on the period from the start of therapy to the end of the study drug administration (3 months). This included: Period 0 – the start of therapy, days 1–14 plus 3 days for testing to confirm the absence of bacterial excretion; Period 1 – days 18–30 + 3 days for testing; Period 2 – days 34–60 + 3 days for testing; Period 3 – days 64–90 + 3 days for testing. For budget impact analysis we used the difference in costs between the two treatment strategies: antituberculosis chemotherapy with IFN-γ injections (the main group) and antituberculosis chemotherapy without IFN-γ (the control group). Efficiency parameters included sputum conversion rates based on microscopy and the median time to clinical response. Cost-effectiveness ratios were calculated using the clinical efficiency of the compared therapies, taking into account sputum smear conversion rates based on microscopy. The results were verified using a one-factor sensitivity analysis based on the cost-effectiveness ratio within a range of ±30%. Results . Pharmacotherapy costs during the first 14 days of hospitalization were higher in the group treated with IFN-γ (12,347,287.00 rubles) compared with the control group (10,723,532.00 rubles). Due to the clinical response achieved, a significantly larger number of patients in the main group are transferred to outpatient care, and costs in Period 1 for this group tend to decrease (1,394,517.12 rubles), while in the control group they are three times higher (4,138,021.76 rubles). Costs in the control group were 3.8 times higher than in the main group in Period 2, and 3.3 times higher in Period 3. Total costs for inpatient care over the 3-month treatment period with the study drug (the main group) were 1.5 times lower than those in the control group. Furthermore, the results were supported by calculations using the time to clinical response, as determined by microscopic examination. These calculations showed that the treatment in the main group was 25.64% more cost-effective than in the control group. The lower cost-effectiveness ratio in the main group compared to the control group (1,401.51 and 1,802.27, respectively) and the higher clinical efficacy in terms of the main criterion indicate that including IFN-γ in the treatment of MDR-TB patients is more cost-effective and preferable. A one-factor sensitivity analysis based on the cost-effectiveness metric confirmed the robustness of the findings to uncertainties and variations in the input data. Conclusion . The results obtained indicate the economic feasibility of adding IFN-γ as a pathogenetic therapy for MDR-TB in combination with antituberculosis chemotherapy.
- Open Access
- 22 March 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (1) , 114-125
Searching for Ideal Oxazolidinone for Treatment of Tuberculosis
Oxazolidinones represent a promising class of drugs for treatment of multidrug-resistant tuberculosis (MDR-TB). Linezolid, the first representative of this class, is highly effective; however, its use is limited due to its toxicity (myelosuppression, neuropathy). 63 publications were analyzed in order to search for new oxazolidinones for treatment of tuberculosis. New drugs and compounds (tedizolid, sutezolid, contezolid, delpazolid, and TBI-223) have a more favorable safety profile with antimycobacterial activity similar to or even greater than that of linezolid. In the coming years, these compounds may become an important component of short, safe, and effective chemotherapy regimens for tuberculosis.
- 22 March 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (1) , 114-125
Open AccessSearching for Ideal Oxazolidinone for Treatment of Tuberculosis
Oxazolidinones represent a promising class of drugs for treatment of multidrug-resistant tuberculosis (MDR-TB). Linezolid, the first representative of this class, is highly effective; however, its use is limited due to its toxicity (myelosuppression, neuropathy). 63 publications were analyzed in order to search for new oxazolidinones for treatment of tuberculosis. New drugs and compounds (tedizolid, sutezolid, contezolid, delpazolid, and TBI-223) have a more favorable safety profile with antimycobacterial activity similar to or even greater than that of linezolid. In the coming years, these compounds may become an important component of short, safe, and effective chemotherapy regimens for tuberculosis.